Future management of diabetes mellitus

Postgraduate Medicine
D E Melnick


A review of therapies for diabetes mellitus reveals little that is new for the diabetic today. Also, there is little evidence that progression of diabetic complications can be slowed or halted with currently available therapeutic modalities that are acceptable to patients and can be applied in an everyday clinical setting. Few new drugs are likely to be ready for marketing in the immediate future, and most of the pharmacologic approaches that are now under study do not address the basic problem of lost sensitivity of the beta cell to endogenous glucose. In the longer term, it is likely that an oral insulin, allowing more convenient management of diabetes, will be available, as well as several new drug classes that may offer therapy adjunctive to insulin. As more is learned of the cellular physiology of the islet cell and the pathology of diabetes mellitus, some additional therapeutic breakthrough may occur. It is highly likely that an implantable or portable infusion system, either of the closed- or open-loop type, will be available when technologic problems are overcome. Islet cell transplantation may provide a definitive treatment for diabetes. At the very least, the questions should be resolved relating to careful physiologi...Continue Reading


Apr 7, 1977·The New England Journal of Medicine·S W Shen, R Bressler
Jul 1, 1977·Drugs·J M Stowers, L J Borthwick
Feb 1, 1978·Metabolism: Clinical and Experimental·P Raskin
Feb 22, 1979·The New England Journal of Medicine·J S FlierJ Roth
Apr 1, 1978·Annals of Internal Medicine·P M Miranda, D L Horwitz
Mar 15, 1979·The New England Journal of Medicine·R A Arky
Sep 1, 1976·Diabetes·A J MatasJ S Najarian
Jan 1, 1977·Annals of Internal Medicine·D J JenkinsG M Alberti
Sep 23, 1976·The New England Journal of Medicine·G Gregoriadis
May 9, 1976·The New England Journal of Medicine·G F CahillN Freinkel


Apr 1, 1983·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·G M Rodin

Related Concepts

Artificial Organs
Blood Glucose
Diabetes Mellitus
Diabetic Diet
Hypoglycemic Effect
Insulin B Chain
Insulin Receptor beta Subunit
Transplantation, Homologous
Islets of Langerhans Transplantation

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.